In vaccine development, a major objective is to induce strong, speci®c T cell responses. This might be obtained by targeting antigen to cell surface molecules that ef®ciently channel the antigen into endocytic compartments for loading of MHC molecules. Antibodies have been used to deliver antigen; however, it is important to de®ne optimal targets on antigen-presenting cells (APC) for ef®cient delivery. For this purpose, we have established a T cell readout that can be used to screen large numbers of different mAb for their ability to load MHC class II molecules. The novel human CD4 + T cell clone is speci®c for mouse Ig C k (40±48) and restricted by HLA-DR4 (DRA1,B1*0401). DR4 apparently presents both mouse and human C k 40±48, but there is no crossreaction at the T cell level. B cells from DR4 transgenic mice spontaneously process and present the mouse C k peptide. The mouse C k -speci®c T cell readout was used to demonstrate that mouse mAb speci®c for human dendritic cell (DC)-speci®c ICAM-grabbing non-integrin (DC-SIGN), a novel DC-speci®c molecule, were 10-to 1000-fold more potent at inducing k-speci®c human CD4 + T cell proliferation compared to control mAb. Consistent with this ®nding, DC-SIGN-speci®c mAb were rapidly internalized upon binding and found in intracellular vesicles. These results strongly argue that DC-SIGN-speci®c mAb are channeled into the MHC class II presentation pathway. Thus, DC-SIGN could be an ef®cient target for antibody-mediated delivery of T cell epitopes in vaccine development.
Introduction
In vaccine development, a major objective is the design of reagents that ef®ciently load MHC molecules with T cell epitopes. CD4 + T cells are central to most adaptive immune responses and antibody-based strategies that target antigen to APC for elicitation of strong, speci®c CD4 + T cell responses are of great value (1±11). It is important to de®ne the most ef®cient cell surface molecules on antigen-presenting cells (APC) to target. A useful strategy to de®ne such targets is to exploit the fact that Ig molecules are themselves processed and presented on MHC class II molecules to CD4 + T cells (12± 14) , and thus use Ig-speci®c T cell clones as reporter reagents. This approach was taken by Lanzavecchia et al. (13) who established human T cell clones speci®c for mouse Ig k, g1 and g2a. These clones have been used by several investigators to establish that mAb directed to MHC class II, transferrin receptor (13) , Ig-like transcript (ILT) 3 (15) and BDCA-2 (16) are ef®ciently processed and presented.
Mouse C k -speci®c T cells are particularly useful because 95% of mouse mAb express k L chains and because only one, non-polymorphic C k exon has been described in the mouse. The k-speci®c clone of Lanzavecchia (13) , however, was not characterized for its ®ne speci®city or HLA restriction. We here describe a novel C k -speci®c T cell clone that is speci®c for mouse Ig C k (residues 40±48) and is restricted by HLA-DRB1*0401 (serologically DR4). This clone should be very useful for screening mouse mAb for their ef®ciency to deliver T cell epitopes for presentation on human MHC class II molecules to human CD4 + T cells.
A reasonable strategy is to target antigen to surface molecules that are exclusively expressed on dendritic cells (DC), as DC are thought to be the most important cells for induction of T cell activation (17) . DC-speci®c ICAM-grabbing non-integrin (DC-SIGN) is a novel DC-speci®c C-type (Ca 2+ -dependent) lectin that is expressed on CD14 + DC precursors in blood as well as on immature and mature DC in peripheral and lymphoid tissues (18) . DC-SIGN is important for contact between resting T cells and DC in T cell areas of secondary lymphoid organs (19) . ICAM-3 expressed on resting T cells binds DC-SIGN with high af®nity. DC-SIGN also binds ICAM-2, an interaction that may regulate chemokine-induced migration from blood (18) . In addition, DC-SIGN binds envelope glycoprotein 120 on HIV and functions as a HIV co-receptor (20, 21) . DC-SIGN does not mediate viral entry itself, but it promotes ef®cient infection in trans of cells that express CD4 and chemokine receptors. Thus, DC expressing DC-SIGN capture HIV-1 in the periphery and transport it to lymphoid organs for infection of cells.
DC-SIGN selectively recognizes endogenous high-mannose oligosaccharides (22, 23) , which have relatively short spacing between terminal mannose residues. Because other sugar-binding C-type lectins, such as mannose receptor (MR), DEC-205 and BDCA-2, function as endocytic receptors that deliver ligands to the MHC class II-loading compartment (16,24±26), DC-SIGN could have a similar function. We have thus investigated whether DC-SIGN-speci®c mAb are internalized and induce proliferation of C k -speci®c CD4 + T cells. If so, DC-SIGN could be an ef®cient DC-speci®c target for antibody-mediated vaccine delivery. We show that mAb speci®c for DC-SIGN are internalized, processed and presented to k-speci®c CD4 + T cells 10-to 1000-fold more ef®ciently than isotype-matched control mAb.
Methods

Antibodies
Puri®ed anti-HLA-DP (B7/21) (27), anti-HLA-DR (28) and panspeci®c HLA class I (W6/32) (29) mouse mAb have been described previously. Rat IgG2b,k with speci®city for mouse IgG2a/2b (HB92) and Ig(5a)7.2 speci®c for the Ig-5a allotype on mouse IgD (TIB149) were obtained from ATCC (Rockville, MD). The aIgD.L6.l2 315 recombinant Troybody with human C g 3 and human C k has been described previously (9) . Fc and F(ab) 2 fragments of mouse Ig were obtained from Pierce (Rockford, IL). L chains from polyclonal mouse Ig, containing 95% k chains, were puri®ed in our laboratory. The 36.1 (IgG2a,l2) and 136.4 (IgG2b,l2) mAb were established from 
Synthetic peptides
Synthetic peptides were synthesized by Fmoc/OtBu chemistry at the Institute of Organic Chemistry, University of Tu È bingen, Germany. Purity was analyzed by reversed-phase HPLC and identity was con®rmed by electrospray mass spectrometry.
Mice
The HLA-DR4 (DRA1 and DRB1*0401) transgenic mice on a B10.Q background (30) were kindly provided by Dr Rikard Holmdahl (Lund, Sweden), as were wild-type B10.Q mice.
Cells and cell lines
Peripheral blood mononuclear cells (PBMC) were puri®ed from whole blood by LymphoPrep density-gradient centrifugation (Nycomed, Oslo, Norway). HLA homozygous Epstein± Barr virus (EBV) cell lines were obtained from the 10th and 11th International Histocompatibility Workshops. Immature DC were cultured from monocytes (adherent PBMC) in the presence of IL-4 (500 U/ml) and granulocyte macrophage colony stimulating factor (800 U/ml; both PeproTech, London, UK) (31) . Maturation of DC was induced by 10 ng/ml lipopolysaccharide (Escherichia coli; Sigma-Aldrich). At day 7, the phenotype of the mature DC was con®rmed by¯ow cytometric analysis. The DC expressed high levels of MHC II, CD86 and CD1a, and low levels of CD14.
Genomic HLA typing
HLA class II alleles were determined at the Institute of Immunology (Dr Frode Vartdal) by the Olerup SSP kit (GenoVision, Saltsjobaden, Sweden).
T cell line and cloning PBMC (2 Q 10 6 /ml) from an individual accidentally exposed to mouse Ig by three separate skin-penetrating needle injuries were cultured with polyclonal mouse IgG (10 mg/ml, Sigma) in 24-well plates. Every 10th day, the T cell line (1 Q 10 6 /ml) was re-stimulated with polyclonal mouse IgG (10 mg/ml) and irradiated (20 Gy) autologous PBMC (1 Q 10 6 /ml) as feeder cells. IL-2 (20 U/ml, Roche Diagnostic, Mannheim, Germany) was added to the cultures on day 1, 3, 5 and 7. After repeated cycles of stimulation, the T cell line was depleted for CD8 + cells by Dynabeads (Dynal, Oslo, Norway) and cloned by limiting dilution in 20 ml Terasaki plates (Nunc, Roskilde, Denmark). As feeder cells, 2 Q 10 4 autologous, irradiated (2000 rad) PBMC were used and the cells were propagated with 1 mg/ml phytohemagglutinin (Wellcome, Dartford, UK) and 20 U/ml IL-2. Clones were expanded and speci®city was tested in proliferation assays. A T cell clone, T18, was selected for further studies and re-stimulated every 10th day with puri®ed k L chains or C k 40±48 peptide and autologous feeder cells. Tissue culture medium was RPMI 1640 with glucose and L-glutamine (Gibco, Paisley, UK) supplemented with pooled 10% human serum from blood donors.
T cell proliferation assay
APC used were PBMC (7 Q 10 4 /well), EBV-transformed cell lines (4 Q 10 4 /well), splenocytes from DR4 (DRA1 and DRB1*0401) transgenic mice or control mice (5 Q 10 5 /well), or DC (1 Q 10 4 /well). Irradiated (8 Gy for mouse splenocytes, 20 Gy for PBMC or 80 Gy for EBV cell lines) APC were cultured in 200-ml cultures in 96-well plates with T cells (4 Q 10 4 /well) and titrated amounts of antigen (synthetic peptides, antibodies or antibody fragments). When DC were used as APC, mAb were added to immature DC and incubated for 4 h prior to addition of lipopolysaccharide (10 ng/ml). After 48 h of APC±T cell coculture, 50 ml of supernatant was collected for cytokine measurements and the cultures were pulsed for 16±24 h with 1 mCi Confocal microscopy DC were cultured for 6±7 days in the presence of granulocyte macrophage colony stimulating factor and IL-4, pulsed with uorescein-labeled DC-SIGN-speci®c mAb (5 mg/ml; 15 or 45 min), and spread onto Cell-Tak (BD Biosciences, Bedford, MA)-coated wells. Confocal images were acquired with a Leica DM IRBE inverted microscope stand equipped with a TCS-NT digital scanning head, using excitation wavelengths of 488 nm. The acquired digital images were processed using Adobe Photoshop 6.0 software.
Results
The T18 CD4 + T cell clone is speci®c for mouse Ig C k 40± 48
PBMC from an individual accidentally sensitized to mouse Ig by needle injuries were stimulated repeatedly every 10th day with polyclonal mouse IgG and autologous APC. After repeated cycles, the speci®city of the line was tested. The line responded equally well to all mouse Ig isotypes tested (IgM, IgG1, IgG2a, IgG2b, IgG3 and IgM) (data not shown). The T cell line was cloned by limiting dilution and two of the clones showed reactivity towards all mouse IgG isotypes. This reactivity pattern suggested that these clones could be speci®c for an epitope located in the invariant C k domain or, less likely, for an H chain determinant shared by all four isotypes.
Among the two clones, the T18 clone was chosen for further studies because it gave the strongest proliferative responses. T18 was CD4 + CD8 ± and had a T h 1 cytokine pro®le since it secreted INF-g, but not IL-4 (data not shown). A number of experiments were performed to determine the speci®city of the CD4 + T cell clone T18. Firstly, the clone responded ef®ciently to a puri®ed free mouse L chain preparation which consists of 95% k chains (Fig. 1A) . Secondly, the clone proliferated in response to mouse F(ab) 2 fragments, but not to Fc fragments (Fig. 1A) . Thirdly, the clone responded to all mouse IgG isotypes and IgM expressing k L chains, whereas IgG2a and IgG2b expressing l2 L chains failed to elicit a proliferative response (Fig. 1B) . These results strongly suggested that the CD4 + T18 T h 1 cell clone is speci®c for a peptide located in the k L chain.
To investigate whether the epitope was located in the variable (V L ) or constant (C L ) region of the k L chain, a recombinant Troybody (aIgD.L3-l2 315 ) (9) that expresses mouse V k and human C k was compared to a mouse antibody [Ig(5a)7.2] that expresses an identical mouse V k , but mouse C k . The recombinant antibody with human C k hardly induced a proliferative response at all, whereas the mouse antibody with mouse C k did (Fig. 1C) . Taken together, this strongly suggested that the T18 T cell clone is speci®c for the mouse C k domain with minimal cross-reaction to the human counterpart.
To determine the stimulating sequence within mouse C k , overlapping 18mer peptides of the entire constant region (103 amino acids) were synthesized. Peptides were tested in a proliferation assay and two overlapping peptides, amino acids 32±49 and amino acids 38±55 of mouse Ig C k exon (sequence according to NCBI protein database), elicited a strong proliferative response, whereas the other peptides were not stimulatory ( Fig. 2A and data not shown) . The stimulating peptides had the overlapping sequence VKWKIDGSERQN (Fig. 2C) . To determine the minimal stimulating epitope, we synthesized additional peptides in which this overlapping sequence was systematically truncated from the N-or Cterminal end. The minimal stimulating epitope was determined to be a 9mer containing residues 40±48 of the C k domain (Fig. 2B and data not shown) . Moreover, there were hardly any cross-reactions to the synthetic 9mers corresponding to the human and rat C k 40±48 sequences (Fig. 2B) . Consistent with this, the clone did not respond to human or rat Ig with k L chains (data not shown). In summary, the CD4 + T h 1 cell clone T18 is species-speci®c for residues 40±48 of the mouse C k domain.
The T18 CD4 + T cell clone is restricted by HLA DRA1,B1*0401
To determine the HLA class II molecule involved in presentation of the mouse k peptide, the donor of the T18 clone was genomically HLA typed and the class II restriction element of the T18 clone was determined by use of EBV-transformed cell lines homozygous for characterized HLA haplotypes. From the two experiments shown in Fig. 3(A) and from the HLA tabulations in Fig. 3(B) , it is evident that the restriction element is DRA1, DRB1*0401 (serologically DR4w4). Indeed, this ®nding is consistent with the observation that mAb speci®c for HLA-DR blocked T cell proliferation, whereas DP-and DQspeci®c mAb did not (data not shown).
In full agreement to the results above, splenocytes from HLA-DR4 (DRA1,DRB1*0401) transgenic mice and control mice (both B10.Q) were tested for their ability to present C k 40±48 to cloned T18 cells in a proliferation assay. Splenocytes from HLA-DR4 transgenic mice elicited a T cell response, whereas non-transgenic control mice did not (Fig. 3C) . Note that HLA-DR4 transgenic splenocytes induced an equally strong proliferative response in the absence of any added k peptide, presumably due to spontaneous processing and presentation of mouse k (Fig. 3C ).
DC incubated with DC-SIGN-speci®c mAb induce proliferation of k-speci®c CD4 + T cells To investigate a possible role of DC-SIGN in antigen capture and antigen presentation, we analyzed the ability of cultured DC to present DC-SIGN-speci®c mAb to the CD4 + HLA-DR4-restricted T cell clone speci®c for mouse C k 40±48 (T18) characterized above. We found that incubating DC with various DC-SIGN-speci®c mAb induced 10-to 1000-fold more ef®cient T cell proliferation compared to isotypematched control mAb (of isotypes IgG1, IgG2a or IgG2b) with irrelevant speci®city (Fig. 4A and B) or compared to ICAM-3 speci®c mAb (IgG1) (Fig. 4A and B) . Thus, the result cannot be explained by uptake via Fc receptors. A panel of six different mAb speci®c for DC-SIGN was tested; the ®ne speci®city of these mAb for discrete antigenic determinants is unknown. Five of them (clones 506, 507, 516, 526 and 530) enhanced responses 100-to 1000-fold, whereas clone 518 was less potent (10-fold) (Fig. 4A) . The enhanced response to anti-DC-SIGN mAb was comparable to the enhanced response obtained with an anti-MR mAb, the latter C-lectin receptor already been shown to function as an endocytic receptor of ligands for MHC class II presentation (25, 26) . 
DC-SIGN-speci®c mAb are internalized upon binding
The results described above strongly argue that DC-SIGN is internalized and intersects the MHC class II pathway. To investigate whether DC-SIGN enters intracellular vesicles upon binding, we incubated DC with¯uorescein-labeled DC-SIGN-speci®c mAb, and analyzed intracellular staining in ®xed and permeabilized cells by confocal microscopy. After a 15-min pulse at 37°C with DC-SIGN-speci®c mAb,¯uorescent staining of the cell membrane was observed (Fig. 5A) . However, after a 45-min pulse at 37°C with mAb, followed by washings and a 45-min chase, DC-SIGN-speci®c mAb was observed in intracellular vesicles (Fig. 5B) . Consistent with this, a putative leucine and tyrosine-based internalization motif (32) has been found in the cytoplasmic domain of DC-SIGN (20) .
Discussion
We have developed a screening system which can easily be used to rapidly screen large numbers of mouse mAb speci®c for human APC surface molecules for their ability to deliver a naturally integrated C k T cell epitope for MHC class II presentation to human CD4 + T cells. Most mouse mAb (95% express k) can be screened with this T cell readout, regardless of the H chain. Similar human CD4 + T cell clones have previously been characterized with speci®cities for mouse IgG1 and IgG2a H chains or k L chain. However, restriction and epitope mapping were not reported (13) .
The T18 CD4 + T cell clone is speci®c for mouse C k 40±48, presented on DR4 (B1*0401). All anchor residues (P1, P4, P6 and P9) in the mouse C k peptide ®t to the proposed binding motif to DRB1*0401 given in the SYFPEITHI-database (http:// www.syfpeithi.de), as do the corresponding rat and human peptides. However, there is little sequence homology between the mouse C k 40±48 and the human C k 40±48 sequence. Importantly, Ma et al. have shown that a human k peptide (145± 159, numbering from the N-terminus), which encompasses the C k 40±48 sequence described in this study, binds with high af®nity to DR4 (33) . Moreover, it was shown that mouse T cells responded to human k 145±159 in the context of DR4. Here we show that the converse is the case, i.e. that a human T cell clone responds to mouse C k 40±48 presented by DR4, but does not cross-react with the corresponding human k sequence. In conclusion, the lack of T cell cross-reactivity between the mouse and the human k peptide is most likely due to TCR contact residues, which differ widely (Fig. 3C ). In addition, tolerance to self k is to be expected (34) and potentially self kreactive T cells should to be deleted in both systems.
Concerning the rat C k 40±48 peptide, there are two substitutions in P6 and P9, compared to the mouse k peptide. Although similar binding properties of both peptides to DRB1*0401 are proposed by the SYFPEITHI-database, we observed no T cell cross-reactivity to the rat k peptide (Fig. 2B) . Consistent with this ®nding, it has been shown that substitutions of anchor residues may alter the surface contour of the peptide±MHC complex as seen by the TCR (35) . Thus, substitutions of anchor residues may introduce conformational changes that affect T cell recognition.
Importantly, splenocytes from HLA-DR4 transgenic mice induced a proliferative response of C k -speci®c T cells even in the absence of any added C k peptide. Presumably, splenocytes in DR4 transgenic mice spontaneously process Igk in vivo and display the C k peptide on DR4, consistent with previous ®ndings in other systems (14,36±38). The splenocytes employed in the assay included both B cells and DC. Whereas DC can be in vivo primed after uptake of soluble Ig in the extracellular¯uid, B cells could process and present endogenous Ig. Both mechanisms could contribute in our experiments.
As much as 30% of the human population expresses DR4. One might ask if these individuals are at special risk for developing human anti-mouse antibodies when treated with mouse mAb. In this respect, the donor of the C k -speci®c T cell clone has antibodies to mouse Ig and the C k -speci®c T cells could have contributed to this antibody response. However, the problem of induction of anti-mouse mAb in patients has been reduced by introduction of humanized mAb for clinical use (39, 40) . The current study is a strong argument that the C k domain should be of human and not mouse origin in antibodies for clinical use.
Antibodies have previously been shown to require intracellular processing before MHC class II presentation (12±14). By use of the C k -speci®c T cell readout, we show that a panel of mAb speci®c for DC-SIGN, a novel DC-speci®c C-type lectin, was 10-to 1000-fold more potent at stimulating kspeci®c CD4 + T cells than isotype-matched control mAb. Thus, the more ef®cient T cell stimulation by anti-DC-SIGN mAb could not be related to unspeci®c uptake via Fc receptors. These data strongly suggest that DC-SIGN, besides functioning as an adhesion receptor, is an endocytic receptor that can ef®ciently deliver its ligands to the MHC class II processing and presentation pathway. This ®nding was corroborated by our observation that anti-DC-SIGN mAb was rapidly endocytosed by DC. While this paper was prepared for submission, Engering et al. (41) published similar results with two different DC-SIGN-speci®c mAb and an IgG1-speci®c, DR0101/DQw1-restricted CD4 + T cell clone as readout. Moreover, it was demonstrated that DC-SIGN is targeted to endosomes/lysosomes after internalization. Taken together, that study and the present suggest that DC-SIGN could be an ef®cient receptor for antibody-mediated delivery of T cell epitopes in vaccine development.
Interestingly, we observed a striking difference in potency for enhanced T cell stimulation between the six distinct DC-SIGN-speci®c mAb. It is dif®cult to relate the difference in potency to isotype (clones were of IgG1, IgG2a and IgG2b isotypes). More likely, the ®ne speci®city for discrete antigenic determinants on DC-SIGN could play a role. Also, the degree of cross-linking and the af®nity of the different mAb could be critical. Fine speci®city and af®nity of mAb are most often unknown; therefore, the functional T cell readout for ability of mAb to deliver the naturally integrated C k epitope for MHC class II presentation should be of great value for selecting the best mAb for antibody-based vaccines. 
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